The fibroblast growth factor receptor pathway in hepatocellular carcinoma

Abstract

Hepatocellular carcinoma is the third most common cause of cancer-related death globally and portends a poor prognosis. The fibroblast growth factor receptor (FGFR) pathway is increasingly acknowledged to play a role in the pathogenesis of hepatocellular carcinoma (HCC) and is postulated to be upregulated as a mechanism of resistance to anti-VEGF treatment. We attempt to review the importance of the FGFR pathway in HCC oncogenesis, as well as the current clinical evidence on the efficacy and safety of FGFR pathway inhibitors in HCC.

Keywords

Hepatocellular carcinoma / targeted therapy / fibroblast growth factor

References

[1] Jemal A,Center MM,Ward E.Global cancer statistics.CA Cancer J Clin2011;61:69-90

[2] Altekruse SF,Reichman ME.Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.J Clin Oncol2009;27:1485-91 PMCID:PMC2668555

[3] Llovet JM,Lachenmayer A.Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Nat Rev Clin Oncol2015;12:408-24

[4] Bruix J,Merle P,Huang YH,Pracht M,Rosmorduc O,Gerolami R,Ross PJ,Bronowicki JP,Kudo M,Llovet JM,LeBerre MA,Meinhardt G,Investigators R.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017;389:56-66

[5] Kelley RK,Cohn AL,Su WC,Braiteh F,Spira A,Lee Y.Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.Ann Oncol2017;28:528-34 PMCID:PMC5391701

[6] Lieu C,Overman M,Kopetz S.Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.Clin Cancer Res2011;17:6130-9 PMCID:PMC5562355

[7] Turner N.Fibroblast growth factor signalling: from development to cancer.Nat Rev Cancer2010;10:116-29

[8] Beenken A.The FGF family: biology, pathophysiology and therapy.Nat Rev Drug Discov2009;8:235-53 PMCID:PMC3684054

[9] Serls AE,Parvatiyar P,Deutsch GH.Different thresholds of fibroblast growth factors pattern the ventral foregut into liver and lung.Development2005;132:35-47

[10] Werner S,Longaker MT,Banda MJ.Large induction of keratinocyte growth factor expression in the dermis during wound healing.Proc Natl Acad Sci U S A1992;89:6896-900 PMCID:PMC49611

[11] Hughes SE.Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues.J Histochem Cytochem1997;45:1005-19

[12] Streuli CH.Signal co-operation between integrins and other receptor systems.Biochem J2009;418:491-506

[13] Nissen LJ,Hedlund EM,Zhao X,Funa K,Cao Y.Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.J Clin Invest2007;117:2766-77 PMCID:PMC1994630

[14] Tille JC,Mandriota SJ,Ferrari S,Zhu Z,Pepper MS.Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.J Pharmacol Exp Ther2001;299:1073-85

[15] Casanovas O,Bergers G.Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.Cancer Cell2005;8:299-309

[16] Kopetz S,Morris JS,Eng C,Adinin R,Valero V,Lieu C,Tran HT,Abbruzzese JL.Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.J Clin Oncol2010;28:453-9 PMCID:PMC2815707

[17] Allen E,Hanahan D.Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.Clin Cancer Res2011;17:5299-310 PMCID:PMC3156934

[18] Helsten T,Arthur E,Carter J.The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing.Clin Cancer Res2016;22:259-67

[19] Dienstmann R,Prat A,Adamo B,Cortes J,Nuciforo P.Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.Ann Oncol2014;25:552-63 PMCID:PMC4433501

[20] Gauglhofer C,Schrottmaier W,Rodgarkia-Dara C,Stattner S,Kandioler D,Schulte-Hermann R,Grusch M,Berger W.Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis.Hepatology2011;53:854-64

[21] Qiu WH,Chu PG,Chung C,Hwu P,Lopez R.Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma.World J Gastroenterol2005;11:5266-72 PMCID:PMC4622793

[22] French DM,Wang M,Shek T,Bolon B,Blackmore C,Rodriguez LA,Venook R,Desnoyers LR.Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.PLoS One2012;7:e36713 PMCID:PMC3352934

[23] Tsunematsu H,Kohga K,Aketa H,Hosui A,Kanto T,Takehara T.Fibroblast growth factor-2 enhances NK sensitivity of hepatocellular carcinoma cells.Int J Cancer2012;130:356-64

[24] Poon RT,Lau C,Fan ST.Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma.Am J Surg2001;182:298-304

[25] Hsu PI,Lai KH,Chan SH,Cheng JS,Ger LP,Yen MY.Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma.Anticancer Res1997;17:2803-9

[26] Asada N,Hayashido Y,Kan M,Nakanishi T,Chayama K.Expression of fibroblast growth factor receptor genes in human hepatoma-derived cell lines.In Vitro Cell Dev Biol Anim2003;39:321-8

[27] Motoo Y,Yamaguchi Y,Nakanuma Y.Sinusoidal capillarization of human hepatocellular carcinoma: possible promotion by fibroblast growth factor.Oncology1993;50:270-4

[28] Sandhu DS,Roberts LR.Fibroblast growth factor signaling in liver carcinogenesis.Hepatology2014;59:1166-73

[29] Wu X,Lemon B,Weiszmann J,Gupte J,Wang Z,Li Y.FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.J Biol Chem2010;285:5165-70 PMCID:PMC2820743

[30] Sawey ET,Cai C,Zhang J,Zhao A,Yee H,French DM,Lowe SW.Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening.Cancer Cell2011;19:347-58 PMCID:PMC3061399

[31] Alvarez-Sola G,Latasa MU,Barcena-Varela M,Jimenez M,Corrales FJ,Berasain C.Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis.Dig Dis2017;35:158-65

[32] Hyeon J,Lee JJ,Park CK.Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.Dig Dis Sci2013;58:1916-22

[33] Miura S,Shimizu H,Yoshidome H,Kato A,Okamura D.Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.BMC Cancer2012;12:56 PMCID:PMC3293719

[34] Nicholes K,Tomlinson E,Wright B,Pham TA,Tsai SP,Stinson J,French DM.A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice.Am J Pathol2002;160:2295-307

[35] Yu C,Jin C,Chan WK.Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice.Am J Pathol2002;161:2003-10

[36] Desnoyers LR,Ferrando RE,Le T,Carano R,Qing J,Ashkenazi A.Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.Oncogene2008;27:85-97

[37] Padrissa-Altes S,Bogorad RL,Rossolini T,Liebisch G,Koteliansky V,Werner S.Control of hepatocyte proliferation and survival by FGF receptors is essential for liver regeneration in mice.Gut2015;64:1444-53

[38] Gao L,Tang Y,Hu CA.FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.J Exp Clin Cancer Res2017;36:8 PMCID:PMC5223586

[39] Llovet JM,Mazzaferro V,Gane E,de Oliveira AC,Raoul JL,Schwartz M,Zeuzem S,Greten TF,Seitz JF,Haussinger D,Shan M,Voliotis D,Group SIS.Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008;359:378-90

[40] Cheng AL,Chen Z,Qin S,Luo R,Ye S,Xu J,Liang H,Wang J,Pan H,Zou J,Guan Z.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol2009;10:25-34

[41] Wilhelm SM,Newell P,Llovet JM.Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther2008;7:3129-40

[42] Gavine PR,Kilgour E,Al-Kadhimi K,Rooney C,Baker D,Brooks AN.AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.Cancer Res2012;72:2045-56

[43] Wohrle S,Beluch N,Stamm C,Muller M,Thuery A,Hynes NE,Hofmann F.FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone.J Bone Miner Res2011;26:2486-97

[44] Gattineni J,Zhang Q,Bates CM.Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4.Am J Physiol Renal Physiol2014;306:F351-8 PMCID:PMC3920047

[45] Nogova L,Perez Garcia JM,Delord JP,Schellens JH,Camidge DR,Vaishampayan U,Tian GG,Wainberg ZA,LoRusso P,Parker K,Choudhury S,Graus-Porta D,Isaacs R,Wolf J.Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study.J Clin Oncol2017;35:157-65

[46] Dienstmann R,Rodon J.Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.Oncologist2011;16:1729-40 PMCID:PMC3248772

[47] Nakamura I,Banini BA,Kim TH,Moser CD,Thornburgh SR,Roberts LR.Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.PLoS One2014;9:e92273 PMCID:PMC3977817

[48] Huynh H,Fargnoli J,Soo KC,Thng CH,Chung A,Pollock P,Tran E.Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.Clin Cancer Res2008;14:6146-53

[49] Park JW,Kim JS,Li RK,Thomas M,Baudelet C,Raoul JL.Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.Clin Cancer Res2011;17:1973-83

[50] Johnson PJ,Park JW,Raoul JL,Hsu CH,Heo J,Lu L,Boucher E,Paik SW,Kudo M,Sobhonslidsuk A,Decaens T,Jeng LB,Ezzeddine R,Cheng AL.Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.J Clin Oncol2013;31:3517-24

[51] Llovet JM,Raoul JL,Kudo M,Kang YK,Lim HY,Mathurin P,Lin DY,Poon RT,Blanc JF,Tak WY,Ezzeddine R,Walters I.Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.J Clin Oncol2013;31:3509-16

[52] Kudo M,Finn RS,Blanc JF,Yang J,Tak WY,Lee JH,Wu C,Shao G,Dela Cruz C,Wang JH.Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial.Hepatology2014;60:1697-707

[53] Huynh H,Tai WM,Chung AY,Soo KC,Linnartz R.Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.J Hepatol2012;56:595-601

[54] Tai WT,Shiau CW,Ko CH,Chen PJ.Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.Mol Cancer Ther2012;11:452-63

[55] Cheng AL,Lim HY,Yang TS,Chao Y,Kudo M,Kang YK,Numata K,Balsara B,Rodriguez AM,Wang Y.Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.Hepatology2016;64:774-84

[56] Kanai F,Tateishi R,Kawabe T,Kondo Y,Tagawa K,Morizane C,Arioka H,Omata M.A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.Cancer Chemother Pharmacol2011;67:315-24

[57] Inaba Y,Aramaki T,Tanaka T,Kaneko S,Imanaka K,Nishida N,Seki H,Arioka H.A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation.Eur J Cancer2013;49:2832-40

[58] Kudo M,Park JW,Liang PC,Izumi N,Lee YJ,Chiu CF,Morita S.Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.Lancet Gastroenterol Hepatol2018;3:37-46

[59] Kudo K,Tanaka K,Furuta K,Kaneda H,Tamura D,De Velasco MA,Saijo N,Nishio K.Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo.Clin Cancer Res2011;17:1373-81

[60] Palmer DH,Peck-Radosavljevic M,Graham J,Deptala A,Schnell D,Loembe AB.A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs.sorafenib in European patients with advanced hepatocellular carcinoma. Br J Cancer2018;118:1162-8 PMCID:PMC5943284

[61] Cheng AL,Kim TY,Chao Y.Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): a randomised phase II trial.J Clin Oncol2013;33:339

[62] Ikeda M,Mitsunaga S,Tamai T,Hayato S,Okita K.Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma.Clin Cancer Res2016;22:1385-94

[63] Ikeda K,Kawazoe S,Ikeda M,Tamai T,Hisai T,Okita K.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.J Gastroenterol2017;52:512-9 PMCID:PMC5357473

[64] Kudo M,Qin S,Ikeda K,Baron A,Han G,Blanc JF,Komov D,Lopez C,Guo M,Kraljevic S,Ren M.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-73

[65] Tabernero J,Dienstmann R,Mita A,Calvo E,Adamo B,Zhong B,Smit JW,Chatterjee-Kishore M,Peddareddigari V,Soria JC.Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors.J Clin Oncol2015;33:3401-8

[66] Loriot Y,Park SH,Huddart RA,Fleming MT,Mellado B,Joshi M,OHagan A OH,Zhong B,Dosne AG,Group OBotBS OB.Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): phase 2 continuous versus intermittent dosing.J Clin Oncol2018;36:411

[67] Hagel M,Sheets M,Weng W,Bifulco N,Hodous B,Shutes A,Lengauer C,Guzi T.First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway.Cancer Discov2015;5:424-37

[68] Kim R,Macarulla T,Choo SP,Hollebecque A,Sung M,Lim HY,Park JW,Mazzaferro V,Schmidt-Kittler O,Wolf B.365OPhase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC).Ann Oncol2017;28:

[69] Javle M,Shroff RT,Springfeld C,Ramanathan RK,Sadeghi S,El-Khoueiry A,Borbath I,Oh DY,Chen LT,Van Cutsem E,Ciombor K,Patel A,Porter D,Zhu AX,Bekaii-Saab T.Phase II Study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma.J Clin Oncol2018;36:276-82 PMCID:PMC6075847

[70] Xie L,Zhang L,Tang L,Xu Y,Liu K,Gao B,Zhang L,Gavine PR,Kilgour E,Ji Q.FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.Clin Cancer Res2013;19:2572-83

[71] Zhang J,Su X,Xie L,Fan S,Xu Y,Dong Z,Qian Z,Schottle J,Ji Q,Smith PD,Thomas RK.Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.Clin Cancer Res2012;18:6658-67

[72] Van Cutsem E,Mansoor W,Chao Y,Ferry DR,Frewer P,Stockman PK,Landers D.A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.Ann Oncol2017;28:1316-24

[73] Bai A,Vo NY,Mazsa EK,Weiler S,Chen T,Jiang J,Gyuris J.GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.Cancer Res2010;70:7630-9

[74] Sommer A,Schatz CA,Mahlert C,Stelte-Ludwig B,Greven S,Braun M,Wittemer-Rump S,Dittmer F,Apeler H,Huynh H,Kreft B.Preclinical efficacy of the auristatin-based antibody-drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors.Cancer Res2016;76:6331-9

[75] Bolos D.Systemic therapy in HCC: lessons from brivanib.J Hepatol2014;61:947-50

[76] Cheng AL,Zhu AX.Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.Oncology2011;81:372-80